Keywords: Spectroscopy, Spectroscopy, Glioma, IDH mutation, brain metabolites, ROC analysis, diagnosis
Motivation: Reliable noninvasive quantification of D-2-hydroxyglutarate (2HG) for diagnosis of isocitrate dehydrogenase (IDH)-mutant gliomas is challenging.
Goal(s): To discriminate between IDH-mutant and wild-type gliomas based on their full metabolic profile.
Approach: Partial Least Squares Discriminant Analysis (PLS-DA) was used to discriminate IDH-mutants from wild-types using in vivo 3T MRS data from 47 patients with a newly diagnosed glioma.
Results: Higher 2HG and lower glutamate + glutamine, glutamate, glycine, and glutathione were observed in IDH-mutants compared to wild-types. The PLS-DA model showed higher accuracy (AUC = 0.949) compared to 2HG alone (AUC = 0.753), underscoring the superiority of a comprehensive approach over single metabolite analysis.
Impact: Exploring in vivo metabolic alterations beyond D-2-hydroxyglutarate is crucial for enhancing diagnostic accuracy in detection of IDH mutations in patients with gliomas, as well as for a deeper understanding of the fundamental biological consequences of this mutation.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords